Thrombosis Research
Volume 125, Issue 3 , Pages 272-277 , March 2010

Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model

Received 25 August 2009 ,Revised 19 October 2009 ,Accepted 21 October 2009.

References 

  1. Pfeifer R, Tarkin IS, Rocos B, Pape HC. Patterns of mortality and causes of death in polytrauma patients—has anything changed?. Injury. 2009;40:907–911
  2. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding—a European perspective. Crit Care. 2006;10:R120
  3. Duchesne JC, Mathew KA, Marr AB, Pinsky MR, Barbeau JM, McSwain NE. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly. Am Surg. 2008;74:1159–1165
  4. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8–15
  5. Rizoli SB, Boffard KD, Riou B, Warren B, Iau P, Kluger Y, et al. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials. Crit Care. 2006;10:R178
  6. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2001;115:998–1001
  7. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;116:619–624
  8. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: A prospective multinational clinical trial. J Thromb Haemost. 2008;6:622–631
  9. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res. 2007;119:643–651
  10. Dickneite G, Dörr B, Kaspereit F, Tanaka KA. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. J Trauma. 2009;67:
  11. Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis-inducing activity in human serum. J Appl Physiol. 1959;14:943–946
  12. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98:790–797
  13. Dickneite G, Pragst I. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. Br J Anaesth. 2009;102:345–354
  14. Diness V, Bregengaard C, Erhardtsen E, Hedner U. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res. 1992;67:233–241
  15. Hemker HC, Giesen P. Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4–15
  16. Dickneite G, Pragst I, Joch C, Bergman GE. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). Blood Coagul Fibrinolysis. doi:10.1097/MBC.0b013e32832da1c5.
  17. Dickneite G, Doerr B, Kaspereit F. Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate. Anesth Analg. 2008;106:1070–1077
  18. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Gordini G, et al. Management of bleeding following major trauma: a European guideline. Crit Care. 2007;11:R17
  19. Schreiber MA, Holcomb JB, Rojkjaer R. Preclinical trauma studies of recombinant factor VIIa. Crit Care. 2005;9(Suppl 5):S25–S28
  20. Blajchman MA, Lee DH. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. Transfus Med Rev. 1997;11:95–105
  21. Tranholm M, Rojkjaer R, Pyke C, Kristensen AT, Klitgaard B, Lollike K, et al. Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits. Thromb Res. 2003;109:217–223
  22. Fattorutto M, Tourreau-Pham S, Mazoyer E, Bonnin P, Raphaël M, Morin F, et al. Recombinant activated factor VII decreases bleeding without increasing arterial thrombosis in rabbits. Can J Anaesth. 2004;51:672–679
  23. Godier A, Mazoyer E, Cymbalista F, Cupa M, Samama CM. Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study. J Thromb Haemost. 2007;5:244–249
  24. Viuff D, Lauritzen B, Pusateri AE, Andersen S, Rojkjaer R, Johansson PI. Effect of 470 haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa 471 (NovoSeven®). Br J Anaesth 2008;101:324–31.
  25. Mann KG, Brummel K, Butenas S. What is all that thrombin for?. J Thromb Haemost. 2003;1:1504–1514
  26. Turecek PL, Váradi K, Keil B, Négrier C, Berntorp E, Astermark J, et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb. 2003;33:16–22
  27. Livnat T, Zivelin A, Martinowitz U, Salomon O, Seligsohn U. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost. 2006;4:192–200
  28. Szlam F, Taketomi T, Sheppard CA, Kempton CL, Levy JH, Tanaka KA. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. Anesth Analg. 2008;106:719–724
  29. Meng ZH, Wolberg AS, Monroe DM, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003;55:886–891
  30. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005;3:640–648
  31. Rodewald L, Scharrer I. Protein chemical investigation of 30 consecutive lots of double-virus eliminated PCC (Beriplex P/N) and summary of safety data. Hämostaseologie. 2004;24:A46
  32. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2:1700–1708

☆ Presented in part at the 53rd Annual Meeting of the Society for Thrombosis and Hemostasis Research, Vienna, Austria, February 4-7, 2009.

PII: S0049-3848(09)00488-5

doi: 10.1016/j.thromres.2009.10.011

Thrombosis Research
Volume 125, Issue 3 , Pages 272-277 , March 2010

Article Tools

* Image Usage & Resolution